OCUL
Ocular Therapeutix Inc · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ocutx.com
- Employees(FY) 274
- ISIN US67576A1007
Performance
+9.04%
1W
-19.62%
1M
-8.6%
3M
+178.67%
6M
+40.58%
YTD
+0.48%
1Y
Profile
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Investment Analysis Report: OCUL
Overview:
OCUL is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $835,457,215. In this report, we will conduct a comprehensive analysis of OCUL's financial statements to provide insights into its valuation, finan...
Technical Analysis of OCUL 2024-05-10
Overview:
In analyzing the technical indicators for OCUL over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for your investm...
Recent News & Updates
- 2024-03-25 19:30
- 2024-03-13 06:38
Q4 2023 Clearside Biomedical Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-03-12 09:55
- 2024-03-11 21:55
- 2024-03-11 17:32
- 2024-03-11 17:25
- 2024-03-11 16:26
Ocular Therapeutix: Q4 Earnings Snapshot(Associated Press Finance)
- 2024-03-11 16:05
- 2024-03-11 05:25
- 2024-03-11 04:05
- 2024-03-05 07:30
- 2024-03-04 18:30
- 2024-03-01 18:30
- 2024-02-29 08:52
- 2024-02-28 19:52
- 2024-02-28 00:40
- 2024-02-26 12:00
- 2024-02-26 10:00
- 2024-02-25 23:00
- 2024-02-25 21:00
- 2024-02-25 14:02
3 Stocks to Buy That Are Up 100% or More in 2024(InvestorPlace)
- 2024-02-22 07:32
- 2024-02-22 07:31
- 2024-02-22 07:30
- 2024-02-21 18:32
- 2024-02-21 18:31
- 2024-02-21 18:30
- 2024-02-21 09:55
- 2024-02-20 20:55
- 2024-02-19 09:00